Loading...
KZR logo

Kezar Life Sciences, Inc.NasdaqCM:KZR Aktienübersicht

Marktkapitalisierung US$53.9m
Aktienkurs
US$7.29
US$6
21.5% überbewertet intrinsischer Abschlag
1Y76.5%
7D-1.2%
1D
Wert des Portfolios
​
Siehe

Kezar Life Sciences, Inc.

NasdaqCM:KZR Lagerbericht

Marktkapitalisierung: US$53.9m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Kezar Life Sciences (KZR) Aktienübersicht

Kezar Life Sciences, Inc. ist ein Biotechnologieunternehmen im klinischen Stadium, das sich mit der Entdeckung und Entwicklung neuartiger niedermolekularer Therapeutika beschäftigt, um ungedeckte Bedürfnisse bei immunvermittelten Krankheiten in den Vereinigten Staaten zu behandeln. Mehr Details

KZR grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung2/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit6/6
Dividenden0/6

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 16.5% pro Jahr sinken.

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Hat keine nennenswerte Marktkapitalisierung ($54M)


KZR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Kezar Life Sciences, Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Kezar Life Sciences
Historische Aktienkurse
Aktueller AktienkursUS$7.29
52-Wochen-HochUS$7.55
52-Wochen-TiefUS$3.53
Beta0.41
1 Monat Veränderung-1.88%
3 Monate Veränderung15.71%
1 Jahr Veränderung76.51%
3 Jahre Veränderung-74.15%
5 Jahre Veränderung-86.37%
Veränderung seit IPO-95.89%

Aktuelle Nachrichten und Updates

Recent updates

Analyseartikel • Dec 08

Is Kezar Life Sciences (NASDAQ:KZR) Using Debt Sensibly?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Oct 03

FDA clears Kezar Life Sciences' drug application for autoimmune hepatitis treatment

Clinical-stage biotech Kezar Life Sciences (NASDAQ:KZR) on Monday said its investigational new drug application for its inhibitor zetomipzomib for the treatment of autoimmune hepatitis (AIH) had been cleared by the U.S. FDA. AIH occurs when the body's immune system attacks the liver, leading to chronic inflammation and damage to liver cells. KZR is evaluating zetomipzomib in a phase 2a clinical trial for the treatment of AIH patients who have not responded to standard of care treatment or have relapsed. The trial aims to enroll 24 patients, and the main goal of the study is the complete response rate, KZR said in a statement. KZR stock +1.3% to $8.90 after hours.
Analyseartikel • Aug 15

Is Kezar Life Sciences (NASDAQ:KZR) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Aug 11

Kezar Life Sciences GAAP EPS of -$0.25 beats by $0.02

Kezar Life Sciences press release (NASDAQ:KZR): Q2 GAAP EPS of -$0.25 beats by $0.02. Cash, cash equivalents and marketable securities totaled $306.8 million.
Seeking Alpha • Jul 27

Kezar Life Sciences: Regulatory Tailwinds Reverse Downside Case

Recent clinical trial momentum has started to inflect positive on the chart for Kezar Life Sciences. The stock has caught a bid in June whilst reducing equity beta to the broad sector, illustrating the sensitivity of its idiosyncratic risk premia. We've also identified a potential mispricing opportunity with a ~38% value gap to the upside, valuing KZR at $13. With this comes an opportunity to harvest alpha over the coming 4-month period into November. These and more points are discussed in this report. Investment summary Recent clinical trial momentum has begun to come through on the chart for Kezar Life Sciences, Inc. (KZR). Following regulatory updates in late June the stock has caught a bid and has our attention as a life sciences play to capture near to medium-term alpha. Here we've identified a potential mispricing to the upside and see a price objective of $13 for KZR over the coming 3-months. We feel the stock will continue breaking away from peers in the sector as investors reward its clinical trial momentum. We estimate the alpha opportunity to last until November, following Q3 earnings. With the view investors will continue to award idiosyncratic risk premia like positive trial readouts in FY22, we rate KZR a buy PT $13. Exhibit 1. KZR 9-month price action Data: Refinitiv Market factors are supportive of further upside We've observed a sharp pullback in growth factors and equity beta this year as investors look to step up in quality. As such, low-beta, high quality plays are optimal for budgeting equity risk in FY22. On that note, we observe two key findings from KZR's investment debate. Firstly, it has strengthened against the benchmark since June, after it first was punished early in that month from a setback in its PRESIDIO Phase 2 trial. Prior to this, it had been strengthening since November 2021. Following its most recent updates, discussed later, the KZR has caught a bid and is now performing against the SPX. Perhaps more importantly, however, is that its covariance structure has been shifting downwards since April and therefore looks to offer investors a source of uncorrelated alpha. Investors are paying a premium for idiosyncratic risk premia in FY22 and the fact KZR is bifurcating away from the broad market to the upside is evidence investors recognize this in the name, by estimation. Exhibit 2. Downshifting covariance structure whilst strengthening against benchmark is a bullish divergence factor Data: Updata Further evidence of this point is seen in the chart below. Firstly, the medical devices and health care equipment sector has also been curling up in H2 FY22. As observed, KZR is strengthening against an already performing sector, a clear differentiating factor. We also observe this isn't just sector beta, given the fact it has reduced correlation to the sector whilst gaining in relative strength, as seen below. Therefore, we believe this to be evidence of the market's rewarding of KZR's idiosyncratic risk premia that is now on offer. Exhibit 3. Further evidence of key differentials at work for KZR with investors outsizing the name versus the sector Data: Updata Regulatory tailwinds In late June, the company posted a set of positive updates from its clinical trial investigating zetomipzomib. It first announced that the MISSION open label Phase 2 trial, investigating zetomipzomib's use as an experimental therapy active lupus nephritis ("ALN"), showed a clinically meaningful response. ALN is a sub-condition of systemic lupus erythematosus ("SLE"), an autoimmune disorder that results in chronic inflammation of the body's connective tissue. It is estimated that ~50% of SLE patients are at risk of developing end-state renal disease that often leads to death. At present, the current standard of treatment is chronic non-steroidal anti-inflammatory ("NSAID") use, dialysis or full kidney transplantation ("FKE"). Zetomipzomib is indicated in usage here as is an immunoproteasome-selective inhibitor identified based on the optimization of ONX-0914. It shows a comparable cytokine inhibition profile peripheral blood mononuclear cells ("PBMC"). For the MISSION trial, the 21-patient cohort was dosed with 60mg of the compound via subcutaneous route 1x weekly as a combination therapy for 24 weeks. Of the group, 17 progressed through the trial, with 65% (11 out of17) of these achieving a ≥50% reduction in urine protein creatinine ratio ("UPCR") compared to baseline. Being a phase 2 trial, investigating safety and efficacy, the treatment was well tolerated with only 2 patients exhibiting serious adverse events. As an add-on, findings also showed that patients in also experienced reductions in extra-renal manifestations of SLE. One of the key benefits the label offers is that it offers an alternative to NSAID's, often the standard of care in SLE management. Long-term NSAID usage is linked to various medical conditions including Cushing's syndrome, peptic ulcers, acute renal failure and cardiovascular issues. Marcum and Hanlon (2010) illustrated that health care providers are often at risk of overprescribing NSAIDs as well. Hence, zetomipzomib has the potential to compete on top of the standard of care as a standalone drug class operating in its own segment. Price action responsive After de-rating substantially in H1 FY22, price action has now turned bullish following this most recent round of updates. In the days after the announcement, the KZR share price rallied over 100% as investors sought to price in the news. Upside has continued and based on the most recent price action we see a cluster of price targets towards $21.70, as seen on Exhibit 4. Shares are testing the first of several inner resistance lines and if it punches up above these this will be bullish confirmation towards our price target. Exhibit 4. Multiple upside targets to $21.70 Data: Updata On a 6-month daily cloud chart, shares have broken back into the cloud and are now trading within cloud support. The lag line is now testing the cloud and we await for this to breakout in order for full conviction on the upward trend. On balance volume has ticked north and suggests long-term volume is still gaining, whilst momentum still remains high as seen below. Exhibit 5. Trading into cloud support Data: Updata Tracing the fibs down from the March high to its May bottom we see the share has already retraced ~38% of the move, where it is currently being tested. We are looking for a bounce from this level to the 50% tab on the fib and this is at ~$11.40. Hence, we look for our next technical objective to be $11.40 from here. Exhibit 6. Data: Updata Valuation With its lack of profitability, assigning a concrete value for KZR is difficult. This is best done through a substantiative DCF, however, given the shifting rates regime and changing capital environment, the predictability of future cash flows is far less certain. However, KZR trades on ~3x book value, below the GICS sector median, as seen below. Exhibit 7. Multiples and comps Data: HB Insights At ~3x book value we would theoretically 'pay' $15, in other words we'd overpay by ~58.5%. We therefore believe KZR could presently be overvalued by that amount, and consequently price at $5.98 apiece, suggesting long-term valuations may already be reflective of the regulatory tailwinds discussed in this report.
Seeking Alpha • Jul 11

Kezar Life Sciences appoints Nick Mordwinkin as chief business officer

Kezar Life Sciences (NASDAQ:KZR) has announced the appointment of Nick Mordwinkin, Pharm.D., Ph.D., as Chief Business Officer. Dr. Mordwinkin will be key to the next stage of Kezar’s growth and will be responsible for shaping the company’s business development strategy. Most recently, he served as Head of Corporate Development, Inflammation and Fibrosis, at Gilead Sciences.
Analyseartikel • Jan 03

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Aug 26

Here's Why We're Not Too Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Apr 05

We're Not Very Worried About Kezar Life Sciences' (NASDAQ:KZR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analyseartikel • Mar 01

Here's What Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Structure Looks Like

If you want to know who really controls Kezar Life Sciences, Inc. ( NASDAQ:KZR ), then you'll have to look at the...
Analyseartikel • Jan 25

Kezar Life Sciences, Inc. (NASDAQ:KZR) Insiders Increased Their Holdings

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
Analyseartikel • Dec 21

Kezar Life Sciences (NASDAQ:KZR) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Aktionärsrenditen

KZRUS BiotechsUS Markt
7D-1.2%1.0%1.3%
1Y76.5%34.2%27.7%

Rendite im Vergleich zur Industrie: KZR übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 34.2 erzielte.

Rendite vs. Markt: KZR übertraf den Markt US, der im vergangenen Jahr eine Rendite von 27.7 erzielte.

Preisvolatilität

Is KZR's price volatile compared to industry and market?
KZR volatility
KZR Average Weekly Movement7.1%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stabiler Aktienkurs: KZR hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: KZRDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
20159Chris Kirkwww.kezarlifesciences.com

Kezar Life Sciences, Inc. ist ein Biotechnologieunternehmen im klinischen Stadium, das sich mit der Entdeckung und Entwicklung neuartiger niedermolekularer Therapeutika zur Behandlung von Krankheiten befasst, für die es in den Vereinigten Staaten einen ungedeckten Bedarf gibt, die durch das Immunsystem verursacht werden. Der führende Produktkandidat des Unternehmens ist Zetomipzomib (KZR-616), ein selektiver Immunoproteasom-Inhibitor für verschiedene Indikationen, darunter Lupusnephritis, Dermatomyositis und Polymyositis, sowie klinische Studien der Phase 1b/2 für systemischen Lupus erythematodes. Kezar Life Sciences, Inc. wurde im Jahr 2015 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.

Kezar Life Sciences, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Kezar Life Sciences im Vergleich zum Marktanteil des Unternehmens?
KZR grundlegende Statistiken
MarktanteilUS$53.86m
Gewinn(TTM)-US$45.23m
Umsatz(TTM)n/a
0.0x
Kurs-Umsatz-Verhältnis
-1.2x
Kurs-Gewinn-Verhältnis

Ist KZR zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
KZR Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$0
Kosten der EinnahmenUS$33.76m
Bruttogewinn-US$33.76m
Sonstige AusgabenUS$11.48m
Gewinn-US$45.23m

Zuletzt gemeldete Gewinne

Mar 31, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-6.12
Bruttomarge0.00%
Nettogewinnspanne0.00%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich KZR auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/13 20:50
Aktienkurs zum Tagesende2026/05/08 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Kezar Life Sciences, Inc. wird von 4 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Maurice RaycroftJefferies LLC
Philip NadeauTD Cowen
Derek ArchilaWells Fargo Securities, LLC